spec sheet10 rows
PRO-LAD is a lysergamide analog of lysergic acid diethylamide (LSD) in which one of the N,N-diethyl substituents is replaced by an n-propyl group. Like LSD it acts primarily as an agonist at the 5-HT2A serotonin receptor, the target that mediates the classic serotonergic psychedelic experience, and it also interacts broadly with other serotonin, dopamine, and adrenergic receptors characteristic of the lysergamide class. Reports place its potency in a range roughly comparable to LSD, producing a qualitatively similar visual and cognitive psychedelic state. Direct pharmacological data on PRO-LAD itself remain sparse; most available evidence comes from systematic studies of closely related N-substituted lysergamides, which are typically characterized in vitro and through the rodent head-twitch response as a behavioral proxy for 5-HT2A activation.
- Classic lysergamide headspace
- Visual and mood changes
- Roughly LSD-like potency
- LSD-like 5-HT2A agonism at comparable potency
- Anxiety or confusion
- Pupil dilation and wakefulness
- Nausea during onset
Mechanism
PRO-LAD acts as a partial at the receptor, the core receptor of the classic psychedelic state, and like other lysergamides it also engages 5-HT2C, , and dopaminergic sites more weakly. The propyl substitution keeps 5-HT2A potency high, so its effect profile resembles LSD's. As with the family, the experience reflects a functional shift in serotonergic signaling rather than tissue toxicity.
receptor fingerprint
receptorpartial agonist
5-HT2C receptoragonist
receptoragonist
Safetyrisks and cautions, not medical advice
PRO-LAD is expected to be physiologically low in toxicity but psychologically powerful, with mindset and setting mattering a great deal; anxiety, confusion, or lasting distress can occur in vulnerable people. Anyone with a personal or family history of psychosis or bipolar disorder should avoid it, and it should not be combined with MAOIs or strongly serotonergic drugs (serotonin toxicity) or with lithium or tramadol (seizure reports). It remains a poorly studied research chemical. Not medical advice.
Subjective profileweighing the evidence above
An LSD analog that is roughly as strong and offers nothing LSD does not, on a far thinner safety record. If novelty is the appeal, that is the entire appeal. The usual psychosis and bipolar cautions apply, and it should never be combined with lithium or tramadol.
Resources
This entry is here for reference.
Research
- 2016first citedReturn of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-…
- 2025most recentThe polypharmacology of psychedelics reveals multiple targets for potential therapeutics.
- 1.Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
- 2.Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)
- 3.The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.
- 4.Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
- 5.Return of the lysergamides. Part II: Analytical and behavioural characterization of N(6) -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).
- 6.Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).
- 7.Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).
- 8.Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).
- 9.Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD).
- 10.Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.
10 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
How is PRO-LAD different from LSD?
It swaps one N-ethyl group for an n-propyl chain; the experience is broadly LSD-like and of similar potency.
What is its mechanism?
Mainly partial agonism at the 5-HT2A serotonin receptor, the shared core of classic psychedelics.
Is it safe to combine with other drugs?
No; MAOIs and strong serotonergic drugs, lithium, and tramadol are particularly risky combinations.
Limitations of the evidence
- Sparse long-term data
Adverse effects
- Anxiety or confusion
- Pupil dilation and wakefulness
- Nausea during onset